Senolytics and Senomorphics Take Aim at Atherosclerosis Inflammation
New review maps how targeting cellular senescence could tackle residual heart disease risk that statins alone can't fix.
Summary
Even with optimal cholesterol-lowering therapy, many older adults with atherosclerosis continue to experience disease progression driven by chronic inflammation. A key culprit is the senescence-associated secretory phenotype (SASP), where aging cells in arterial plaques release inflammatory signals that destabilize plaques. This review examines two drug strategies: senolytics, which eliminate senescent cells entirely, and senomorphics, which suppress the harmful signals those cells emit. Drugs like dasatinib plus quercetin, fisetin, and lanatoside C selectively kill senescent vascular cells, while rapamycin, metformin, and JAK inhibitors quiet their inflammatory output. Preclinical evidence shows both approaches reduce plaque size, limit necrotic cores, and improve stability. However, major gaps in dosing, safety, and clinical trial data remain before widespread use in older cardiovascular patients.
Detailed Summary
Cardiovascular disease remains the leading cause of death globally, and a growing body of evidence points to chronic vascular inflammation as a key driver of atherosclerosis progression even in patients receiving optimal lipid-lowering therapy. This so-called residual inflammatory risk is now linked to cellular senescence and the senescence-associated secretory phenotype (SASP), making senotherapeutics a compelling new frontier in cardiovascular medicine.
This 2026 narrative review synthesizes current evidence on how SASP contributes to atherosclerosis and evaluates two complementary pharmacological strategies. Senescent endothelial cells, vascular smooth muscle cells, and foam cells accumulate within atherosclerotic plaques and secrete pro-inflammatory cytokines including IL-1α, IL-6, and MCP-1, along with matrix metalloproteinases that weaken plaque structure and promote rupture risk.
Senolytics — including the dasatinib-quercetin combination, fisetin, and lanatoside C — work by disabling the anti-apoptotic survival mechanisms (BCL-2, PI3K/AKT, HSP90) that allow senescent cells to persist. By eliminating these cells, senolytics have demonstrated reductions in plaque burden, necrotic core expansion, and improved plaque stability in preclinical models. Senomorphics such as rapamycin, metformin, and JAK/STAT or NF-κB inhibitors take a different approach, attenuating SASP output without necessarily killing the cells, potentially offering safer long-term use profiles.
Preclinical results are encouraging across both drug classes, but the review highlights critical translational gaps. These include uncertainty around optimal patient selection criteria, appropriate dosing regimens, potential interactions with existing cardiovascular medications, and long-term safety in elderly populations who may be more vulnerable to off-target effects.
The review concludes that targeting SASP represents a scientifically rational strategy to address residual inflammatory risk in atherosclerosis. Rigorous clinical trials specifically designed for geriatric cardiovascular populations are urgently needed to move these promising agents into clinical practice.
Key Findings
- SASP-secreting senescent cells in plaques release IL-1α, IL-6, MCP-1, and MMPs that drive plaque vulnerability.
- Senolytics (dasatinib+quercetin, fisetin, lanatoside C) clear senescent cells by blocking BCL-2, PI3K/AKT, and HSP90.
- Senomorphics (rapamycin, metformin, JAK/STAT inhibitors) suppress SASP signaling without eliminating senescent cells.
- Preclinical data show both strategies reduce plaque area, necrotic core size, and improve plaque stability.
- Major clinical gaps remain in dosing, drug interactions with cardiovascular drugs, and long-term geriatric safety.
Methodology
This is a narrative review synthesizing preclinical and emerging clinical evidence on senotherapeutics in atherosclerosis. No original data were collected; findings are drawn from existing literature on SASP biology, senolytic pharmacology, and cardiovascular disease models. The authors declare no use of AI tools in preparation.
Study Limitations
This is a review based solely on preclinical and early-phase evidence; no randomized clinical trial data in cardiovascular populations are yet available for most senotherapeutics. Patient selection criteria, optimal dosing, and drug-drug interactions with anticoagulants or antihypertensives remain undefined. Long-term safety in elderly patients with polypharmacy is a significant unresolved concern.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: